Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

A systematically derived exposure assessment instrument for Chronic Hypersensitivity Pneumonitis.

Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR; CHP Exposure Assessment Collaborators.

Chest. 2020 Jan 17. pii: S0012-3692(20)30022-2. doi: 10.1016/j.chest.2019.12.018. [Epub ahead of print]

PMID:
31958445
2.

Dynamics of human monocytes and airway macrophages during healthy aging and after transplant.

Byrne AJ, Powell JE, O'Sullivan BJ, Ogger PP, Hoffland A, Cook J, Bonner KL, Hewitt RJ, Wolf S, Ghai P, Walker SA, Lukowski SW, Molyneaux PL, Saglani S, Chambers DC, Maher TM, Lloyd CM.

J Exp Med. 2020 Mar 2;217(3). pii: e20191236. doi: 10.1084/jem.20191236.

PMID:
31917836
3.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
4.

The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis.

Spagnolo P, Molyneaux PL, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F, Tiné M, Saetta M, Maher TM, Balestro E.

Int J Mol Sci. 2019 Nov 10;20(22). pii: E5618. doi: 10.3390/ijms20225618. Review.

5.

Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.

Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M, Braybrooke R, Molina-Molina M, Hobbs BD, Putman RK, Sakornsakolpat P, Booth HL, Fahy WA, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Whyte MKB, Zhang Y, Kaminski N, Adegunsoye A, Strek ME, Neighbors M, Sheng XR, Gudmundsson G, Gudnason V, Hatabu H, Lederer DJ, Manichaikul A, Newell JD Jr, O'Connor GT, Ortega VE, Xu H, Fingerlin TE, Bossé Y, Hao K, Joubert P, Nickle DC, Sin DD, Timens W, Furniss D, Morris AP, Zondervan K, Hall IP, Sayers I, Tobin MD, Maher TM, Cho MH, Hunninghake GM, Schwartz DA, Yaspan BL, Molyneaux PL, Flores C, Noth I, Jenkins RG, Wain LV.

Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201905-1017OC. [Epub ahead of print]

PMID:
31710517
6.

Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA.

Eur Respir J. 2019 Nov 14. pii: 1901681. doi: 10.1183/13993003.01681-2019. [Epub ahead of print] No abstract available.

PMID:
31699833
7.

Methods in Lung Microbiome Research.

Carney SM, Clemente JC, Cox MJ, Dickson RP, Huang YJ, Kitsios GD, Kloepfer KM, Leung JM, LeVan TD, Molyneaux PL, Moore BB, O'Dwyer DN, Segal LN, Garantziotis S; ATS Allergy, Immunology and Inflammation Assembly Working Group on Microbiome in Lung Disease.

Am J Respir Cell Mol Biol. 2019 Oct 29. doi: 10.1165/rcmb.2019-0273TR. [Epub ahead of print]

PMID:
31661299
8.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Nov;36(11):3059-3070. doi: 10.1007/s12325-019-01093-3. Epub 2019 Sep 29.

9.

Right Ventricular to Left Ventricular Ratio at CT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease.

Bax S, Jacob J, Ahmed R, Bredy C, Dimopoulos K, Kempny A, Kokosi M, Kier G, Renzoni E, Molyneaux PL, Chua F, Kouranos V, George P, McCabe C, Wilde M, Devaraj A, Wells A, Wort SJ, Price LC.

Chest. 2020 Jan;157(1):89-98. doi: 10.1016/j.chest.2019.06.033. Epub 2019 Jul 24.

PMID:
31351047
10.

Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort.

Organ LA, Duggan AR, Oballa E, Taggart SC, Simpson JK, Kang'ombe AR, Braybrooke R, Molyneaux PL, North B, Karkera Y, Leeming DJ, Karsdal MA, Nanthakumar CB, Fahy WA, Marshall RP, Jenkins RG, Maher TM.

Respir Res. 2019 Jul 12;20(1):148. doi: 10.1186/s12931-019-1118-7.

11.

The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis.

Invernizzi R, Molyneaux PL.

Eur Respir Rev. 2019 Jul 8;28(152). pii: 190045. doi: 10.1183/16000617.0045-2019. Print 2019 Jun 30. Review.

12.

Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis.

Barnett J, Molyneaux PL, Rawal B, Abdullah R, Hare SS, Vancheeswaran R, Desai SR, Maher TM, Wells AU, Devaraj A.

Eur Respir J. 2019 Jul 25;54(1). pii: 1900531. doi: 10.1183/13993003.00531-2019. Print 2019 Jul.

PMID:
31164428
13.

The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis.

Allden SJ, Ogger PP, Ghai P, McErlean P, Hewitt R, Toshner R, Walker SA, Saunders P, Kingston S, Molyneaux PL, Maher TM, Lloyd CM, Byrne AJ.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):209-219. doi: 10.1164/rccm.201809-1775OC.

14.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

15.

Evaluation of a re-useable bronchoscopy biosimulator with ventilated lungs.

Garner JL, Garner SD, Hardie RJ, Molyneaux PL, Singh S, Kemp SV, Shah PL.

ERJ Open Res. 2019 Apr 15;5(2). pii: 00035-2019. doi: 10.1183/23120541.00035-2019. eCollection 2019 Apr.

16.

In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality.

Mackintosh JA, Desai SR, Adamali H, Patel K, Chua F, Devaraj A, Kouranos V, Kokosi M, Margaritopoulos G, Renzoni EA, Wells AU, Molyneaux PL, Kumar S, Maher TM, George PM.

Eur Respir J. 2019 May 23;53(5). pii: 1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May. No abstract available.

PMID:
30923184
17.

The Challenging Road of Moving from Association to Causation for Microbiome Research in Idiopathic Pulmonary Fibrosis.

Segal LN, Molyneaux PL.

Am J Respir Crit Care Med. 2019 May 1;199(9):1054-1056. doi: 10.1164/rccm.201902-0318ED. No abstract available.

18.

A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.

Lukey PT, Harrison SA, Yang S, Man Y, Holman BF, Rashidnasab A, Azzopardi G, Grayer M, Simpson JK, Bareille P, Paul L, Woodcock HV, Toshner R, Saunders P, Molyneaux PL, Thielemans K, Wilson FJ, Mercer PF, Chambers RC, Groves AM, Fahy WA, Marshall RP, Maher TM.

Eur Respir J. 2019 Mar 18;53(3). pii: 1801992. doi: 10.1183/13993003.01992-2018. Print 2019 Mar.

PMID:
30765508
19.

The potential impact of azithromycin in idiopathic pulmonary fibrosis.

Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, Maher TM, George PM, Renzoni EA, Molyneaux PL.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb. No abstract available.

PMID:
30442715
20.

PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.

Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, Chioma OS, Lee G, Hassell NE, Shaginurova GI, Wang Y, Johnson JE, Kerrigan A, Mason WR, Baughman RP, Ayers GD, Bernard GR, Culver DA, Montgomery CG, Maher TM, Molyneaux PL, Noth I, Mutsaers SE, Prele CM, Peebles RS Jr, Newcomb DC, Kaminski N, Blackwell TS, Van Kaer L, Drake WP.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaar8356. doi: 10.1126/scitranslmed.aar8356.

Supplemental Content

Loading ...
Support Center